Doctor of Philosophy

Peter Nobel Descendant of Nobel Family Shares the Mission and Vision of Nobel Sustainability Trust and Nobel DAO at MIT

Retrieved on: 
Wednesday, April 24, 2024
Bitcoin, Doctor of Philosophy, Great Dome, Ecosystem, Computer science, NST, Communication, Research, Student, Artificial intelligence, Intelligence, Faculty, Friction, Ageing, MIT, Cryptocurrency

Mr. Nobel also highlighted the development blueprint of Nobel DAO, an innovative platform for top global talents.

Key Points: 
  • Mr. Nobel also highlighted the development blueprint of Nobel DAO, an innovative platform for top global talents.
  • Mr. Nobel mentioned several unique aspects of Nobel DAO:
    First, Nobel DAO adopts a unique membership system, recruiting tech elites aged 13-35 with an IQ above 140.
  • This event built a bridge of communication between MIT faculty, students and the Nobel Sustainability Trust and also Nobel DAO.
  • It also conveyed the vision and mission of Nobel DAO to more young tech elites, which will undoubtedly bring more support for its future development.

APEGA concludes annual general meeting, Tracey Stock installed as 105th president

Retrieved on: 
Thursday, May 2, 2024
Margaret Allan, Courage, FEC, Doctor of Philosophy, APEGA, Motion, Engineering, Bank statement, Annual report, Quality of life, AGM

APEGA leadership delivered updates, including annual addresses by the outgoing and incoming presidents, and by the registrar and CEO (RCEO).

Key Points: 
  • APEGA leadership delivered updates, including annual addresses by the outgoing and incoming presidents, and by the registrar and CEO (RCEO).
  • Council election results were presented and ratified, marking the formal installation of the 2024-25 APEGA council with Tracey Stock, KC, P.Eng., PhD, FEC, as APEGA’s 105th president.
  • Stock, an energy industry leader and avid volunteer, has previously served terms as an APEGA councillor, vice-president and president-elect.
  • In their addresses, President Stock and past-president Plante thanked RCEO Jay Nagendran, P.Eng., for his service to the professions, as he announced he will retire in April 2025.

Codexis Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Maple syrup urine disease, Element, Investment, SAB, RNA interference, MBBS, Alnylam Pharmaceuticals, MSUD, Ligation, Research and development, Control, Doctor of Philosophy, HCU, Administration, Roche, DNA, Senior, ECO, Marketing, MBA, Former, Advertising, GMP, Telephone, Biotechnology, McGill University, Fine chemical

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance
    REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • Total revenues increased by 32% to $17.1 million for first quarter 2024 compared to $13.0 million in first quarter 2023.
  • Product revenues increased by 14% to $9.6 million for first quarter 2024 compared to $8.4 million in first quarter 2023.
  • Product gross margin was 49% for first quarter 2024 compared to 46% in first quarter 2023.

American Nurses Association Presents Nurses Week 2024 – Nurses Make the Difference

Retrieved on: 
Thursday, May 2, 2024
ANA, FAAN, Social media, Health, Nursing, MD, Doctor of Philosophy, Life, American Nurses Association, RN, Caregiver, Face, Workforce, MBA

SILVER SPRING, MD, May 02, 2024 (GLOBE NEWSWIRE) -- The American Nurses Association (ANA), the professional organization representing and investing in the interests of all nurses, is proud to lead the annual Nurses Week (May 6-12) celebration.

Key Points: 
  • SILVER SPRING, MD, May 02, 2024 (GLOBE NEWSWIRE) -- The American Nurses Association (ANA), the professional organization representing and investing in the interests of all nurses, is proud to lead the annual Nurses Week (May 6-12) celebration.
  • This year’s Nurses Week theme is “Nurses Make the Difference” to encourage nurses, health care professionals, employers, community leaders and the public to recognize and promote the vast contributions and positive impact of nurses worldwide.
  • For resources to celebrate National Nurses Week, visit the Nurses Week 2024 website for more information regarding upcoming activities.
  • The American Nurses Association (ANA) is the premier organization representing the interests of the nation's more than 5 million registered nurses.

GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

Retrieved on: 
Thursday, May 2, 2024
American Diabetes Association, Abstract, Diabetes, Doctor of Philosophy, TTP, Longevity, Medical device

Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced two abstracts have been accepted for poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions to be held June 21-24, 2024 in Orlando, FL.

Key Points: 
  • Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced two abstracts have been accepted for poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions to be held June 21-24, 2024 in Orlando, FL.
  • The ADA Scientific Sessions is one of the premier diabetes conferences which provides a platform for the latest advancements in diabetes research, prevention, and care.
  • This annual meeting provides researchers and health care professionals with the unique opportunity to share ideas and learn about cutting edge technologies and breakthroughs in diabetes research and diabetes-related conditions.
  • “We look forward to presenting two posters discussing the preclinical animal studies and the sensor longevity simulation modeling for our Continuous Blood Glucose Monitor (CBGM)” said Paul V. Goode, PhD, CEO of Glucotrack.

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

Retrieved on: 
Friday, April 26, 2024
Phase, HKEX, European Commission, Marketing, MAA, CHMP, CRC, Partnership, Doctor of Philosophy, European, Patient, EMA, Medicine, Committee, Civil service commission, European Medicines Agency, Pharmaceutical industry

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its partner Takeda (TSE:​4502/​NYSE:​TAK) received notification that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended the approval of fruquintinib for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”).

Key Points: 
  • The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for metastatic CRC throughout the European Union (“EU”), Norway, Liechtenstein and Iceland.
  • “Through our partnership with HUTCHMED, we have made strides in expanding access to fruquintinib to eligible patients.
  • With this positive CHMP opinion for fruquintinib, we are one step closer to potentially offering patients in the EU an oral, chemotherapy-free option that can provide a significant survival benefit,” said Awny Farajallah, M.D., Chief Medical Officer, Oncology at Takeda.
  • People living with metastatic CRC in the EU currently have limited treatment options available to them, which can lead to poor outcomes.

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Retrieved on: 
Friday, April 26, 2024
Stargardt disease, The Association, Safety, Retinitis pigmentosa, Armada, NR2E3, Gardian, Research, Doctor of Philosophy, Vaccine, Retina, Research and development, Patient, Geographic atrophy, Clinical trial, Annual general meeting, ARVO, Pharmaceutical industry

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial) at The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.

Key Points: 
  • MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial) at The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.
  • “With three gene therapies to treat blindness diseases currently in the clinic, now is an exciting time for Ocugen and the patients who can potentially benefit from our first-in-class modifier gene therapy platform,” said Dr. Shankar Musunuri, Chairman, CEO and Co-founder of Radius.
  • “We look forward to sharing more about the scientific foundation of our programs and providing clinical updates with industry leaders during ARVO.”
    Ocugen’s presence at ARVO 2024 includes:
    Title: OCU400 Nuclear Hormone Receptor-Based Gene Modifier Therapy: Safety and Efficacy from Phase 1/2 Clinical Trial for Retinitis Pigmentosa Associated with NR2E3 and RHO Mutations
    Presenter: Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen
    Ocugen is committed to bringing game-changing therapies to treat inherited retinal diseases as well as blindness diseases affecting millions to market and working even harder to provide access to patients globally.

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Retrieved on: 
Friday, April 26, 2024
Cancer, Safety, Regenerative medicine, TS, Metastasis, Trial of the century, Doctor of Philosophy, Development, Disease, CIRM, Autoimmune disease, Kite Pharma, Research and development, Patient, RCC, CD70, AACR, Clinical trial, Kidney cancer, Therapy, SAN, Pharmaceutical industry

It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.

Key Points: 
  • It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.
  • The grant will support the ongoing Phase 1 TRAVERSE trial which assesses safety, tolerability and preliminary efficacy of ALLO-316 in advanced RCC that has progressed despite standard therapy.
  • Additionally, the grant will support translational and clinical analyses to inform a recommended Phase 2 regimen.
  • A more comprehensive data update from the ongoing trial is planned for later in 2024.

Fujifilm Introduces First-of-its-Kind Transducer for On-Pump Intracardiac Echocardiography Imaging (OPIE) for Septal Myectomy

Retrieved on: 
Friday, April 26, 2024
FDA, Cardiothoracic surgery, AATS, TTE, Tech, Ventricular septal defect, Heart, Cleveland Clinic, Facial muscles, MD, Doctor of Philosophy, NYU, FACS, Indocyanine green, Cardiology, Fujifilm, OPIE, TEE, Division, Medical imaging

Lexington, MA,, April 26, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the launch of its first-of-kind OPIE Transducer for on-pump intracardiac echocardiography (OPIE) for septal myectomy.

Key Points: 
  • Lexington, MA,, April 26, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the launch of its first-of-kind OPIE Transducer for on-pump intracardiac echocardiography (OPIE) for septal myectomy.
  • However, with OPIE, a thin transducer is passed into the heart during the myectomy where images of the patient’s septal thickness can be seen in real-time.
  • A study featuring Fujifilm’s OPIE Transducer highlights that the system provides established imaging to aid in septal myectomy procedures compared to TEE and transthoracic echocardiogram (TTE).
  • Real-time measurements of the interventricular septal thickness are crucial during septal myectomy to avoid creating a ventricular septal defect while resecting enough myocardium.

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Retrieved on: 
Thursday, April 25, 2024
Doctor of Philosophy, Infection, Safety, Pandemic, Pharmacokinetics, ESCMID, Science, Therapy, Liver, MBA, Government, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.
  • The presentation highlights ALG-097558 Phase 1 data showing that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect.
  • “We are pleased to present these ALG-097558 data, which further highlight the best-in-class potential of this pan-coronavirus protease inhibitor and its substantial differentiation versus current standard of care coronavirus antiviral drugs like nirmatrelvir/ritonavir (PAXLOVIDTM),” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “These data further demonstrate that Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates.